SOURCE: PURE Bioscience, Inc.

PURE Bioscience, Inc.

October 20, 2014 08:36 ET

PURE Bioscience Hosts Year-End Results Conference Call October 28, 2014 to Review Progress of SDC Antimicrobial-Based Food Safety Solutions Strategy

SAN DIEGO, CA--(Marketwired - Oct 20, 2014) - PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company will host an investor conference call on Tuesday, October 28, 2014 at 1:30pm PDT (4:30pm EDT).

In addition to discussion of fiscal year end 2014 results, the PURE management team will review the latest progress made in commercializing SDC as a food safety solution:

  • Quick Service Restaurants (QSRs) Status
    • Completed 650 store SUBWAY® Restaurants market test during fiscal Q4 2014.
      • Initiation of a phased system-wide sales rollout with SUBWAY® in the US.
  • FDA/USDA Applications for Direct Food Contact Status
    • Review process of SDC as a processing aid
      • For reduction of Salmonella in poultry
      • For reduction of Salmonella, E.coli and Listeria in produce
      • Initial SDC testing status for reduction of Salmonella and E.coli in beef and pork

The Participant Dial-In Number for the conference call is 1-631-982-4565. Participants should dial in to the call at least five minutes before 1:30pm PDT (4:30pm EDT) on October 28th, 2014. The call can also be accessed "live" online at http://public.viavid.com/index.php?id=111020.

A replay of the webcast will be available on the Company's website (http://www.purebio.com/about/investor_relations). Also, a replay of the conference call will be available by dialing 1-877-870-5176 (international participants dial 1-858-384-5517) starting October 28th, 2014, at 7:30pm Eastern Time through November 11th, 2014 at 11:59 pm Eastern Time. Please use PIN Number 90611.

Forward-looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the Company's cash position and liquidity requirement;, the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including acceptance of the Company's Hard Surface disinfectant by SUBWAY franchisees; the ability of the Company to develop effective new products and receive regulatory approvals of such products; competitive factors; dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission; including our quarterly report on Form 10-Q filed on June 10, 2014. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contact Information

  • IR Contacts:
    Tom Hemingway
    Redwood Investment Group
    714-978-4425
    Email Contact

    Terri MacInnis, Director of IR
    Bibicoff + MacInnis, Inc.
    818-379-8500
    Email Contact

    Company Contact:
    Peter C. Wulff
    CFO & COO
    PURE Bioscience, Inc.
    619-596-8600 ext.111
    Email Contact